|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Net product sales | |||||
| Collaboration revenue (ZURZUVAE) | |||||
| Royalty, licensing, and other revenues | |||||
| Total revenues | |||||
| Costs and expenses | |||||
| Cost of revenues | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Amortization of intangible assets | |||||
| Intangible asset impairment charges | |||||
| Contingent consideration loss (gain) | |||||
| Total costs and expenses | |||||
| Operating earnings (loss) | |||||
| Other income (expense) | |||||
| Interest and other income, net | |||||
| Interest expense | |||||
| Total other income (expense), net | |||||
| Earnings (loss) before income taxes | |||||
| Income tax expense (benefit) | |||||
| Net earnings (loss) | |||||
| Earnings (Loss) per share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...